The aim of DoReMi is to promote the sustainable integration of low dose risk research in Europe in order to aid the effective resolution of the key policy questions identifies by the High Level Expert Group (HLEG) on Low Dose Risk Research (www.hleg.de). DoReMi provides an operational tool for the development of the proposed MELODI platform consisting of major national bodies and research programs that have long term commitment in low does risk research in Europe. A letter of Intent between the core members of MELODI has been signed in April 2009. During the project, new members are expected to join the Initiative. The Joint Programme of Activities (JPA) of DoReMi includes: (i) a Joint Programme of Research (JPR) covering the issues outlined above and providing an overview of the needs for research infra-structures of pan-European interest and facilitating multilateral initiatives leading to better use and development of research infrastructures; (ii) a Joint Programme of integration (JPI) to develop a coordinated European roadmap for the long term needs of the key players in Europe; and (iii) a Joint Programme for the Spreading of Excellence (JPSE), covering knowledge management, training and mobility and its implementation. The JPR focuses on the areas identified by the HLEG as the most promising in terms of addressing / resolving the key policy questions, namely: the shape of dose response curve for cancer, individual susceptibilities and non-cancer effects. Radiation quality, tissue sensitivity and internal exposures will be addresses as cross cutting themes within the three main research areas. A substantial proportion of the JPA will be dedicated to the joint programme of research. The programme describes a multidisciplinary approach including interfaces with the broader biological toxigo-logical and epidemiological communities. Strategic planning will be carried out in close collaboration with MELODI. The long term Strategic Research Agenda (SRA) will be developed by MELODI, whereas DoReMi research priorities are based on a shorter term Transitional Research Agenda (TRA), focusing on goals that are feasible to achieve within the 6 years project and areas where barriers need to be removed in order to proceed with the longer term strategic objectives.    «

The aim of DoReMi is to promote the sustainable integration of low dose risk research in Europe in order to aid the effective resolution of the key policy questions identifies by the High Level Expert Group (HLEG) on Low Dose Risk Research (www.hleg.de). DoReMi provides an operational tool for the development of the proposed MELODI platform consisting of major national bodies and research programs that have long term commitment in low does risk research in Europe. A letter of Intent between the...    »